论文部分内容阅读
目的探讨术前新辅助治疗联合术中灌注化疗对中低位直肠癌患者预后的影响。方法将92例中低位直肠癌患者随机分为观察组和对照组,每组46例,对照组给予常规手术治疗,观察组给予术前新辅助治疗联合术中灌注化疗后行手术治疗,观察两组患者治疗疗效。结果观察组手术时间、术中出血量均显著低于对照组(P<0.05),两组患者手术并发症发生率比较差异无统计学意义(P>0.05);观察组患者术后1年内局部复发率、远处转移率均显著低于对照组(P<0.05);观察组患者远期生存率显著高于对照组(P<0.05)。结论术前新辅助治疗联合术中灌注化疗可降低中低位直肠癌患者局部复发率、提高远期生存率。
Objective To investigate the effect of preoperative neoadjuvant therapy combined with intraoperative perfusion chemotherapy on the prognosis of low and middle rectal cancer patients. Methods 92 cases of low and middle rectal cancer patients were randomly divided into observation group and control group, 46 cases in each group, the control group given conventional surgery, the observation group given preoperative neoadjuvant therapy combined with intraoperative perfusion chemotherapy after surgery, observed two Group patients treatment efficacy. Results The operation time and intraoperative blood loss in the observation group were significantly lower than those in the control group (P <0.05). There was no significant difference in the incidence of surgical complications between the two groups (P> 0.05) The recurrence rate and distant metastasis rate were significantly lower than those in the control group (P <0.05). The long-term survival rate in the observation group was significantly higher than that in the control group (P <0.05). Conclusions Neoadjuvant chemotherapy and intraoperative perfusion chemotherapy can reduce the local recurrence rate and improve the long-term survival rate in patients with low or middle rectal cancer.